Glaxo Smith Kline results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements.
Net profit-34.85 millionEGP · −362.6% vs the same period a year earlier
Total assets4.53 billionEGP · +22.1% vs the same period a year earlier
Shareholders' equity2.03 billionEGP · +5.5% vs the same period a year earlier
Operating cash flow34.01 millionEGP · −78.1% vs the same period a year earlier
In short
- Glaxo Smith Kline's net profit for Q3 2025 was about -34.85 million EGP, down −362.6% from 13.27 million EGP in Q3 2024.
- Total assets at the end of Q3 2025 were about 4.53 billion EGP, and shareholders' equity about 2.03 billion EGP.
- Operating cash flow for Q3 2025 was positive at 34.01 million EGP.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit-34.85 million13.27 million−362.6%
Gross profit118 million186 million−36.7%
Total assets4.53 billion3.71 billion+22.1%
Total liabilities—1.78 billion—
Shareholders' equity2.03 billion1.93 billion+5.5%
Total liabilities and equity4.53 billion3.71 billion+22.1%
Operating cash flow34.01 million155 million−78.1%
Investing cash flow-5.82 million-34.29 million+83.0%
Financing cash flow-2.6 million-84.17 million+96.9%
Net change in cash25.59 million36.91 million−30.7%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Glaxo Smith Kline's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy